Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials
Authors' conclusion
Our findings suggest that earlier treatment with canagliflozin confers consistent cardiorenal benefits to individuals with type 2 diabetes.
Study context
- Population
- Participants with T2D in the CANVAS Program and CREDENCE trial, by 5-year intervals of diabetes durationCANVAS N = 10,142
- Comparison
- Canagliflozin vs placebo by T2D duration
- Outcome
- CV and kidney outcomes by T2D duration subgroup
Methodological detailssubgroup analysis by 5-year intervals of diabetes duration
- Subgroup analysis by 5-year intervals of diabetes duration
Pooled result
As reported in the abstract
- Canagliflozin benefit across intervals of diabetes duration, with no heterogeneity for MACE, cardiovascular (CV) death or HF hospitalization, and kidney failure requiring therapy or doubling serum creatinine
- Canagliflozin reduced albuminuria progression and increased albuminuria regression, with no interaction across all diabetes duration subgroups
Original publication
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials. Diabetes Care. Published 22 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →